Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Jürgen Weitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5760-6391; OpenAlex author ID A5014919291. Sources: OpenAlex.

Their work

Papers
51 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
2
Collaborators
110
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 6 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 3 papers · 2022: 6 papers · 2023: 7 papers · 2024: 1 paper · 2025: 5 papers · 2026: 4 papers

Papers 50 of 51

  1. A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions. Co-author DOI 10.1038/s41698-026-01678-6↗
  2. Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. Co-author DOI 10.1172/jci.insight.194290↗
  3. Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-026-19628-8↗
  4. ASO Visual Abstract: Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Sur… Co-author DOI 10.1245/s10434-026-19708-9↗
  5. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  6. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Co-author DOI 10.1038/s41416-024-02915-0↗
  7. The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients. Co-author DOI 10.1038/s44276-025-00150-5↗
  8. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. Co-author DOI 10.1097/as9.0000000000000545↗
  9. Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial. Co-author DOI 10.3389/fonc.2025.1602933↗
  10. Molecular Spectroscopy for the Biochemical Composition Analysis of Patient-Derived Pancreatic Cancer Organoids. Co-author DOI 10.1002/cam4.70457↗
  11. [Familial pancreatic cancer syndrome]. First author DOI 10.1007/s00104-023-01819-8↗
  12. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. Co-author DOI 10.1038/s41698-023-00459-9↗
  13. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0258↗
  14. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Co-author DOI 10.1186/s12943-023-01880-1↗
  15. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Co-author DOI 10.1186/s13045-023-01404-w↗
  16. RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy. Co-author DOI 10.3233/cbm-220460↗
  17. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers15082326↗
  18. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Co-author DOI 10.1002/path.5906↗
  19. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  20. [Ampullary Carcinoma-prognostic and Therapeutical Contrast to Pancreatic Ductal Adenocarcinoma]. First author DOI 10.1055/a-1775-9024↗
  21. Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectroscopy. Co-author DOI 10.1117/1.jbo.27.7.075001↗
  22. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Co-author DOI 10.1172/jci.insight.152761↗
  23. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14051216↗
  24. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinica… Co-author DOI 10.1007/s00066-020-01654-4↗
  25. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
  26. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers13061297↗
  27. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-020-03367-8↗
  28. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Co-author DOI 10.1038/s41388-020-1186-7↗
  29. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers12102756↗
  30. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Co-author DOI 10.1155/2019/1024614↗
  31. Erratum to "CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids". Co-author DOI 10.1155/2019/9209764↗
  32. Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. Co-author DOI 10.3390/cells8020142↗
  33. The "T" now Matters: The Eighth Edition of the Union for International Cancer Control Classification of Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000002531↗
  34. Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2017.08.157↗
  35. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Co-author DOI 10.1038/s41598-017-08165-w↗
  36. Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer: A Single-center Experience With 483 Patients. Co-author DOI 10.1097/sla.0000000000001808↗
  37. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3225-5↗
  38. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. Co-author DOI 10.15252/emmm.201607354↗
  39. Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.20315↗
  40. Top-down approach to the superior mesenteric artery and the mesopancreas during pancreatoduodenectomy for pancreatic cancer. Last author DOI 10.1002/jso.24204↗
  41. Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection. Co-author DOI 10.1245/s10434-016-5515-6↗
  42. Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. Co-author DOI 10.3892/ijo.2016.3505↗
  43. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
  44. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Co-author DOI 10.1155/2014/474905↗
  45. AB0 blood group and prognosis in patients with pancreatic cancer. Last author DOI 10.1186/1471-2407-12-319↗
  46. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients… Co-author DOI 10.1186/1471-2407-12-361↗
  47. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-7-28↗
  48. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1097/sla.0b013e31823ac299↗
  49. Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. Co-author DOI 10.1186/1471-2407-11-134↗
  50. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. Last author DOI 10.1186/1471-2407-11-275↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lena Seifert · 18 shared papers, 2020–2026 · strength 3.28
  2. Adrian M. Seifert · 17 shared papers, 2018–2026 · strength 2.75
  3. Marius Distler · 20 shared papers, 2014–2025 · strength 2.53
  4. Max Heiduk · 12 shared papers, 2020–2026 · strength 1.81
  5. David Digomann · 9 shared papers, 2021–2026 · strength 1.70
  6. Christoph Kahlert · 12 shared papers, 2011–2025 · strength 1.54
  7. Thilo Welsch · 17 shared papers, 2011–2022 · strength 1.50
  8. Sebastian Hempel · 7 shared papers, 2016–2026 · strength 1.27
  9. Florian Oehme · 5 shared papers, 2023–2026 · strength 1.13
  10. Franziska Baenke · 5 shared papers, 2022–2026 · strength 0.96
  11. Loreen Natusch · 4 shared papers, 2025–2026 · strength 0.96
  12. Daniel E. Stange · 6 shared papers, 2019–2026 · strength 0.96
  13. Christian Teske · 6 shared papers, 2016–2025 · strength 0.91
  14. Marc Schmitz · 6 shared papers, 2020–2026 · strength 0.84
  15. Mathieu Pecqueux · 5 shared papers, 2017–2026 · strength 0.76
  16. Sarah Cronjaeger · 3 shared papers, 2026 · strength 0.74
  17. Michael B. Ghadimi · 3 shared papers, 2023–2026 · strength 0.66
  18. Ioana Plesca · 4 shared papers, 2021–2023 · strength 0.54
  19. Bo Kong · 2 shared papers, 2025 · strength 0.42
  20. Nuh N. Rahbari · 7 shared papers, 2011–2023 · strength 0.41
  21. Christoph Reißfelder · 6 shared papers, 2011–2020 · strength 0.41
  22. Robert Grützmann · 4 shared papers, 2014–2022 · strength 0.40
  23. Gerald R. Steiner · 2 shared papers, 2022–2024 · strength 0.40
  24. Fang Cheng Wong · 2 shared papers, 2023–2025 · strength 0.31
  25. Yi Han · 2 shared papers, 2023–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.